196 related articles for article (PubMed ID: 27338043)
1. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
Sha LY; Zhang Y; Wang W; Sui X; Liu SK; Wang T; Zhang H
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2201-8. PubMed ID: 27338043
[TBL] [Abstract][Full Text] [Related]
2. MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway.
Fan YX; Dai YZ; Wang XL; Ren YQ; Han JJ; Zhang H
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2194-200. PubMed ID: 27338042
[TBL] [Abstract][Full Text] [Related]
3. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy.
Zheng S; Fu W; Huang Q; Zhou J; Lu K; Gu J; Ma R; Guo G
Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):431-442. PubMed ID: 36732923
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
5. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
7. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
Zhao PW; Cui JX; Wang XM
Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.
Liu M; Gong C; Xu R; Chen Y; Wang X
Cell Mol Biol Lett; 2019; 24():47. PubMed ID: 31308851
[TBL] [Abstract][Full Text] [Related]
10. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Ma T; Zhang J; Wu J; Tang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
[TBL] [Abstract][Full Text] [Related]
11. MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27.
Ren YQ; Fu F; Han J
Med Sci Monit; 2015 May; 21():1297-303. PubMed ID: 25943633
[TBL] [Abstract][Full Text] [Related]
12. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
[TBL] [Abstract][Full Text] [Related]
13. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
14. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
15. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
[TBL] [Abstract][Full Text] [Related]
16. Expression of miR-335 in triple-negative breast cancer and its effect on chemosensitivity.
Hao J; Lai M; Liu C
J BUON; 2019; 24(4):1526-1531. PubMed ID: 31646803
[TBL] [Abstract][Full Text] [Related]
17. MiR-26a-5p Heightens Breast Cancer Cell Sensitivity to Paclitaxel via Targeting Flap Endonuclease 1.
Cai Y; Zhang T; Chen G; Liu C
Ann Clin Lab Sci; 2023 Jan; 53(1):116-125. PubMed ID: 36889769
[TBL] [Abstract][Full Text] [Related]
18. Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200.
Li CY; Miao KL; Chen Y; Liu LY; Zhao GB; Lin MH; Jiang C
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6008-6014. PubMed ID: 30280784
[TBL] [Abstract][Full Text] [Related]
19. Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines.
Wilhelm CA; Clor ZJ; Kelts JL
Anticancer Res; 2018 Sep; 38(9):5043-5048. PubMed ID: 30194148
[TBL] [Abstract][Full Text] [Related]
20. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
Chen F; Luo N; Hu Y; Li X; Zhang K
Cell Physiol Biochem; 2018; 47(5):2147-2158. PubMed ID: 29975921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]